KEY POINTS
- This retrospective analysis of a prospectively maintained database from Institut Curie included 75 consecutive patients with solitary plasmacytoma treated between 2004 and 2025. Thirty-three patients received radiotherapy plus lenalidomide–dexamethasone, while 42 received radiotherapy alone. Solitary bone plasmacytoma accounted for 65 patients (86.7%), and solitary extramedullary plasmacytoma for ten (13.3%). Median follow-up was 6.31 years, with comparable follow-up between groups.
- Radiotherapy was delivered using VMAT or helical tomotherapy, with a median prescription of 40 Gy (range 20–46 Gy). In the combined-treatment group, lenalidomide 25 mg daily on days 1–21 of a 28-day cycle for four cycles was started concurrently with RT, together with dexamethasone 40 mg weekly. Treatment allocation was nonrandomized and primarily reflected referring hematologists' practice preferences rather than predefined eligibility criteria.
- Progression-free survival was significantly longer with combined treatment, with 10-year PFS of 71.8% versus 26.7% after RT alone, a difference of 45.1 percentage points. Five-year PFS was 71.8% versus 49.1%, respectively (log-rank p=0.008). In univariable Cox regression, lenalidomide–dexamethasone was associated with reduced progression risk (HR 0.315, 95% CI 0.128–0.775; p=0.012).
- Systemic progression was less frequent among patients receiving lenalidomide–dexamethasone, occurring in 6/33 (18.2%) versus 21/42 (50.0%) after RT alone. Ten-year systemic progression-free survival was 71.8% versus 33.0%, with a significant treatment association (HR 0.347, 95% CI 0.140–0.861; p=0.023). The six events after combined treatment comprised three cases of multiple myeloma and three cases of multiple plasmacytomas.
- Multiple myeloma-free survival was not significantly improved, despite numerical separation at ten years (86.6% vs 65.9%; p=0.19). Across the entire cohort, 12 patients (16.0%) developed multiple myeloma, 11 (14.7%) developed multiple plasmacytomas, and five (6.7%) developed a distant solitary plasmacytoma. Local control was excellent regardless of systemic treatment, with only three local recurrences (4.0%) and 91.2% ten-year local recurrence-free survival.
- The strongest association was observed in solitary bone plasmacytoma. Among 65 patients, ten-year PFS was 70.4% with combined treatment versus 15.9% with RT alone (p=0.003), while ten-year systemic progression-free survival was 70.4% versus 22.0% (p=0.007). In contrast, the ten-patient extramedullary subgroup showed no significant PFS difference, but included only two patients receiving combined therapy, preventing reliable subgroup conclusions.
- Long-term treatment-related toxicity was not systematically reassessed in this analysis. The previously reported initial cohort documented grade 1 radiation dermatitis and pain flare in approximately 22%, without significant treatment-group differences, while hematologic toxicity was numerically more frequent with lenalidomide–dexamethasone and no grade 4–5 events were reported. Interpretation is limited by nonrandomized allocation, treatment-era differences, evolving staging practices, and the small number of patients remaining at risk for ten-year estimates.
CLINICAL TAKEAWAY
Adding lenalidomide–dexamethasone to definitive radiotherapy was associated with substantially improved long-term progression-free survival in solitary plasmacytoma, particularly solitary bone plasmacytoma. However, the nonrandomized design, lack of a statistically significant multiple myeloma-free survival benefit, and incomplete long-term toxicity assessment mean that routine combined treatment requires further prospective validation.
SOURCE
International Journal of Radiation Oncology, Biology, Physics